State of the ART: Applying Up-to-Date Safety and Tolerability Data to Individualize HIV Care

Download All
In this comprehensive educational program, expert faculty discuss the latest updates on ART safety and tolerability issues, focusing on unique populations such as pregnant women, aging patients, populations with cardiometabolic toxicities, and transgender persons.
Joseph J. Eron, Jr., MD
Darcy Wooten, MD


If you had told me 25 years ago that we would be obsessed with weight gain, I would have thought you were crazy. Yet here I am in clinic trying to decide what to do with possible ARV medication–related weight gain.

Joseph J. Eron, Jr., MD Released: October 31, 2022

Two-drug ART continues to be a nice simplification strategy for people with HIV. Read my commentary on recent data presented at the Fall 2022 Conferences highlighting safety and tolerability of 2-drug regimens.

Darcy Wooten, MD Released: December 23, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings